SUDA Pharmaceuticals Ltd. appointed David Simmonds to the Board as a non-executive Director, effective 27 March 2019. David was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. David was a member of the Australian Auditing and Assurance Standards Board (AUASB) from 2006 to 2013. David is currently a member of the Board and chairs the Audit, Risk and Finance Committee of MS Research Australia, the largest national not-for-profit body dedicated to funding and coordinating multiple sclerosis research in Australia.